부산대학교 도서관

New types of targeted molecular therapies are becoming available in metastatic colorectal cancer (mCRC). Bevacizumab, a humanized anti-VEGF antibody, used with chemotherapy prolongs survival and delays tumor progression in patients with mCRC. Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in mCRC KRAS exon 2 wild-type tumors. Bevacizumab or Cetuximab with FOLFOX or FOLFIRI offer similar, extended survival in mCRC. The results from this trial suggest that drug selection should be based on anticipated adverse effects rather than efficacy. Regorafenib is an oral multikinase inhibitor used for the treatment of patients with mCRC. The most common side effects of regorafenib are fatigue, decreased appetite, hand-foot skin reaction, diarrhea, and hypertension. An intra-individual titration study is needed in the management of regorafenib for patients who would not like to have serious side effects during chemotherapy.